This happens, for example, also when taking medications for diabetes, schizophrenia and other psychiatric conditions
Retatrutide (LY3437943) simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved dual or single agonists such as tirzepatide and semaglutide
Backed by years of scientific research, CarnoSyn is the only patented beta-alanine on the market
Some aspects of the research appear promising, while others remain unproven: What appears promising so far: Reduced substance-seeking behavior observed in animal models Anecdotal and observational reports of decreased cravings in some individuals Growing scientific interest in shared reward pathways between appetite and addiction What remains unproven or unclear: Whether observed effects lead to sustained recovery outcomes How GLP-1s affect the psychological and social dimensions of addiction Whether benefits, if present, are consistent across substances or populations Differences in study design also limit interpretation: Animal trials do not reliably predict human outcomes Observational data cannot establish causation Controlled human trials remain small, limited, and inconsistent Safety considerations are equally important and must be weighed carefully: Common side effects include nausea, appetite suppression, and gastrointestinal distress Changes in appetite or weight may interact with existing mental health symptoms For individuals with eating disorders, appetite-suppressing effects may pose particular risks Given these uncertainties, GLP-1 medications should not replace evidence-based addiction treatments
